Bioverativ Inc Share Price

Stocks

27/04/18	Sanofi : sees new acquisitions and drugs reviving growth	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
28/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
15/02/18	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
07/02/18	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
30/01/18	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
22/01/18	Stocks hit record as senators reach deal to end shutdown	RE
22/01/18	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
22/01/18	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
22/01/18	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

06/03/18	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
14/02/18	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
13/02/18	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
24/01/18	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
24/01/18	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

29/03/18	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
08/03/18	Sanofi finalise l'acquisition de Bioverativ
08/03/18	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
23/02/18	Sanofi : franchit une étape dans son offre sur Bioverativ
07/02/18	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy Harris PRN	Corporate Officer/Principal	76	31/01/2017
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	07/03/2018
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
WUXI APPTEC CO., LTD.	+4.98%	+5.73%	+54.45%	+113.83%	74.33B
ARGENX SE	-0.39%	+0.02%	+38.84%	+83.28%	62.26B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+7.68%	+32.24%	+24.27%	27.72B
INSMED INCORPORATED	+0.83%	-3.43%	-16.41%	+359.38%	26.42B
BIONTECH SE	+2.02%	-0.87%	+1.85%	-7.92%	24.62B
GENMAB A/S	0.00%	+6.81%	+25.03%	-11.44%	20.72B
PHARMAESSENTIA CORPORATION	-2.54%	-3.36%	+149.64%	+324.48%	15.01B
EXELIXIS, INC.	-1.95%	+1.80%	+42.69%	+165.15%	14.18B
SUMMIT THERAPEUTICS INC.	-5.32%	-8.25%	-10.53%	+823.50%	13.48B
Average	-0.24%	+0.54%	+35.31%	+208.28%	30.97B
Weighted average by Cap.	+1.00%	+2.13%	+36.59%	+149.59%

Employees

Sector